Research programme: HIV-1 nucleocapsid protein inhibitors - ImQuest

Drug Profile

Research programme: HIV-1 nucleocapsid protein inhibitors - ImQuest

Alternative Names: HIV-1 NCp7 protein inhibitors - ImQuest Biosciences; Virus-inactivating NCp7-targeted thioesters - ImQuest Biosciences

Latest Information Update: 11 Aug 2008

Price : $50

At a glance

  • Originator ImQuest BioSciences
  • Class Small molecules
  • Mechanism of Action HIV zinc finger inhibitors; Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 06 Aug 2008 Preclinical development is ongoing in USA
  • 01 Jun 2004 Preclinical trials in HIV-1 infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top